Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Online Access: | https://doi.org/10.5281/zenodo.19117779 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <p>The concurrent use of herbal supplements and antiretroviral drugs is increasingly prevalent,<br>particularly among individuals living with HIV/HBV, raising important concerns about<br>herb-drug interactions (HDIs). Dandelion root (Taraxacum officinale) is one of the most widely<br>consumed herbal products worldwide, valued for its diuretic, hepatoprotective,<br>anti-inflammatory, and antioxidant properties. Tenofovir, available as tenofovir disoproxil<br>fumarate (TDF) and tenofovir alafenamide (TAF), is a cornerstone nucleotide reverse<br>transcriptase inhibitor used in the management of HIV and hepatitis B virus (HBV) infections.<br>This review critically evaluates the pharmacokinetic and pharmacodynamic mechanisms by<br>which dandelion root may interact with tenofovir, with emphasis on renal transporter-mediated<br>interactions, diuretic effects on drug elimination, P-glycoprotein modulation, and shared<br>nephrotoxic potential. Available evidence from in vitro studies, animal models, and clinical case<br>reports is synthesized to provide clinicians with a comprehensive risk framework. The review<br>concludes with clinical recommendations and proposes areas for future investigation.</p>